Adding lapatinib to trastuzumab may improve progression-free survival in women whose HER2-positive metastatic breast cancer progressed on a previous trastuzumab regimen, according to a paper published online ahead of print in the Journal of Clinical Oncology.

This entry was posted on Monday, February 8th, 2010 at 10:39 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.